Front Med (Lausanne). 2026 Jun 24;13:1853642. doi: 10.3389/fmed.2026.1853642. eCollection 2026.
ABSTRACT
INTRODUCTION: The prognostic significance of the computed tomography (CT)-defined emphysema phenotype in patients hospitalized with mild-to-moderate acute exacerbation of chronic obstructive pulmonary disease (AECOPD) remains poorly defined.
MATERIALS AND METHODS: This prospective multicenter cohort study analyzed data from the MAGNET AECOPD Registry. We included patients hospitalized with mild-to-moderate AECOPD (Rome criteria) who underwent chest CT within 24 h of admission. Participants were categorized into emphysema and non-emphysema groups based on visual CT assessment. The primary outcome was 3-year all-cause mortality; secondary outcomes included rehospitalization and in-hospital events. Propensity score matching balanced baseline characteristics.
RESULTS: Among 5,713 eligible patients, 4,558 (79.8%) had emphysema. After 1:1 propensity score matching (n = 2,258), the emphysema group demonstrated more severe acute disease, with higher proportions of respiratory failure (12.1% vs. 3.4%, p < 0.001), and elevated inflammatory markers (all p < 0.001). Interestingly, the emphysema group exhibited significantly lower 3-year all-cause mortality (24.8% vs. 30.2%, log-rank p = 0.048) despite higher rates of non-invasive ventilation requirement (24.1% vs. 19.1%, p = 0.005) and longer hospital stays (11 vs. 10 days, p < 0.001). The non-emphysema group carried a heavier burden of cardiovascular comorbidities including hypertension (41.5% vs. 32.7%, p < 0.001) and heart failure (18.7% vs. 13.6%, p = 0.001).
CONCLUSION: In mild-to-moderate AECOPD, the emphysema phenotype predicts higher acute morbidity yet lower long-term mortality. This finding suggests potential distinct pathophysiological pathways and supports further investigation of CT-based phenotyping for personalized management in COPD.
CLINICAL TRIAL REGISTRATION: http://www.chictr.org.cn/showproj.aspx?proj=121626, Identifier ChiCTR2100044625.
PMID:42422826 | PMC:PMC13341661 | DOI:10.3389/fmed.2026.1853642